Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWM4D0)

• Drug Name: Futibatinib Drug Info
• Synonyms: TAS-120

Indication

Disease Entry	ICD 11	Status	REF
Intrahepatic cholangiocarcinoma	2C12.10	Approved	[1]
Cholangiocarcinoma	2C12.10	Phase 3	[2]
Multiple myeloma	2A83	Phase 1/2	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]

• Cross-matching ID:
  PubChem CID: 71621331
  CAS Number: CAS 1448169-71-8
  TTD Drug ID: DMWM4D0

Molecule-Related Drug Atlas

Drug(s) Targeting Fibroblast growth factor receptor (FGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erdafitinib	DMI782S	Bladder cancer	2C94	Approved	[6]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[4]
HIF-1alpha	DM4OQRD	Lymphoma	2A80-2A86	Phase 4	[7]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[4]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[4]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
BAY1163877	DMCSGJ2	Bladder cancer	2C94	Phase 2	[9]
ICP-192	DM524GR	Bladder cancer	2C94	Phase 2	[10]
PRN1371	DMR7BAO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
PD173074	DMP0N4U	Nasopharyngeal carcinoma	2B6B	Investigative	[7]

Drug(s) Targeting Fibroblast growth factor (FGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Recombinant acidic fibroblast growth factor	DM8HVNR	Skin burns	ME65.0	Phase 3	[11]
GSK3052230	DMCKNJX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor (FGFR)	TT0LF7H	NOUNIPROTAC	Antagonist	[5]
Fibroblast growth factor (FGF)	TT5HU6Z	NOUNIPROTAC	Inhibitor	[4]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214801.
• [2] ClinicalTrials.gov (NCT04093362) Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02052778) A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [7] Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
• [8] The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
• [9] Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
• [10] Clinical pipeline report, company report or official report of InnoCare Pharma.
• [11] Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Mol Endocrinol. 1990 Jun;4(6):869-79.
• [12] National Cancer Institute Drug Dictionary (drug id 599037).